Other Clinical Trial - A Phase 1 Study of IXAZOMIB in Adult Patients With

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This is an open-label, multicenter, phase 1, dose escalation study of IXAZOMIB. The primary purpose of this study is to determine the safety profile, establish the maximum tolerated dose, and inform the phase 2 dose of IXAZOMIB administered intravenously in participants with nonhematologic malignancies.

See also
Status	Clinical Trial	Phase
Terminated	`NCT00915278` - A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors	Phase 1
Completed	`NCT01653158` - CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies	Phase 1
Completed	`NCT00948467` - Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies	Phase 1

NCT number	NCT00830869
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 1
Start date	March 2, 2009
Completion date	April 20, 2012

A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms